Bumps in the Road
If the FDA decides that the benefits of a drug outweigh the known risks, the drug will receive approval and can be marketed in the United States. But if there are problems with an NDA or if more information is necessary to make that determination, the FDA may issue a complete response letter.
Common problems include unexpected safety issues that crop up or failure to demonstrate a drug's effectiveness. A sponsor may need to conduct additional studies--perhaps studies of more people, different types of people, or for a longer period of time.
Manufacturing issues are also among the reasons that approval may be delayed or denied. Drugs must be manufactured in accordance with standards called good manufacturing practices, and the FDA inspects manufacturing facilities before a drug can be approved. If a facility isn't ready for inspection, approval can be delayed. Any manufacturing deficiencies found need to be corrected before approval.
"Sometimes a company may make a certain amount of a drug for clinical trials. Then when they go to scale up, they may lose a supplier or end up with quality control issues that result in a product of different chemistry," says Kweder. "Sponsors have to show us that the product that's going to be marketed is the same product that they tested."
John Jenkins, M.D., director of CDER's Office of New Drugs, says, "It's often a combination of problems that prevent approval." Close communication with the FDA early on in a drug's development reduces the chance that an application will have to go through more than one cycle of review, he says. "But it's no guarantee."
The FDA outlines the justification for its decision in a complete response letter to the drug sponsor and CDER gives the sponsor a chance to meet with agency officials to discuss the deficiencies. At that point, the sponsor can ask for a hearing, correct any deficiencies and submit new information, or withdraw the application.
Cowen Maintains an Outperform rating on XOMA, Ltd. (NASDAQ: XOMA), ahead of EYEGUARD-B trial data. Analyst Phil Nadeau said that consultants believe EYEGUARD-B is likely to hit its primary endpoint. Data is expected to be released mid-July. Nadeau commented, "In advance of the mid-July data release from gevokizumab BUY LADIES
You have a comment on ever post, talk about time
Go find a friend, much healthier , if it makes your losses in this stock only bareable by insanely insisting that every poster lost money in clbs, good for you .
You need help my good person.
I feel sorry for your spouse, tells us, be a true person and tell us how much money have you lost.
I will swear on my children souls that I have not lost one penny on clbs, can you do the same